CINECA IRIS Institutional Research Information System

SAINAS, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.483
EU - Europa 1.819
AS - Asia 585
AF - Africa 32
SA - Sud America 28
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.955
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.408
IT - Italia 651
IE - Irlanda 292
CN - Cina 262
SE - Svezia 198
DE - Germania 131
FR - Francia 102
GB - Regno Unito 99
AT - Austria 89
IN - India 78
UA - Ucraina 67
CA - Canada 64
VN - Vietnam 51
HK - Hong Kong 44
FI - Finlandia 32
SG - Singapore 31
BE - Belgio 25
JP - Giappone 23
KR - Corea 21
IR - Iran 20
NL - Olanda 20
PL - Polonia 19
DK - Danimarca 18
BR - Brasile 14
CZ - Repubblica Ceca 12
NG - Nigeria 12
SN - Senegal 12
PT - Portogallo 10
CH - Svizzera 9
ES - Italia 9
ID - Indonesia 9
PK - Pakistan 8
AR - Argentina 7
MY - Malesia 7
TR - Turchia 7
AU - Australia 6
GR - Grecia 6
IQ - Iraq 6
MX - Messico 6
BG - Bulgaria 5
BZ - Belize 5
HR - Croazia 5
TW - Taiwan 5
CO - Colombia 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
CI - Costa d'Avorio 3
PH - Filippine 3
RS - Serbia 3
TH - Thailandia 3
CL - Cile 2
EG - Egitto 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
MA - Marocco 2
MK - Macedonia 2
RO - Romania 2
RU - Federazione Russa 2
SA - Arabia Saudita 2
BD - Bangladesh 1
BO - Bolivia 1
IL - Israele 1
LV - Lettonia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 4.955
Salva come PNG Salva come JPEG
Città #
Chandler 457
Dublin 291
Nyköping 138
Torino 131
Turin 118
Los Angeles 110
Ann Arbor 102
Vienna 89
Beijing 88
Medford 81
Ashburn 72
Jacksonville 71
Princeton 62
Woodbridge 58
Dearborn 55
Houston 54
Fairfield 50
Redwood City 50
Wilmington 42
Fremont 41
Milan 36
Villeurbanne 36
Dong Ket 33
Seattle 26
Rome 25
Cambridge 23
Guangzhou 23
Pisa 22
Brussels 21
Ottawa 21
Shanghai 20
Nanjing 19
New York 19
Québec 17
Boston 15
Hangzhou 14
Washington 14
Copenhagen 13
Menlo Park 13
Abuja 12
Boardman 12
Central 12
Munich 12
Singapore 12
West Jordan 12
Hefei 11
Warsaw 11
Delhi 10
Paris 10
Toronto 10
Bari 8
Bradford 8
Chengdu 8
Chennai 8
Gunzenhausen 8
Tai Wan 8
Viterbo 8
Hebei 7
Jakarta 7
Leeds 7
Lisbon 7
Novara 7
Riverside 7
Alessandria 6
Amsterdam 6
Cassano Magnago 6
Epsom 6
Florence 6
Leinì 6
Piemonte 6
Rivoli 6
San Diego 6
Barcelona 5
Belize City 5
Helsinki 5
Jinan 5
Liverpool 5
Naples 5
Norwalk 5
Reston 5
San Jose 5
San Mateo 5
Uppsala 5
Valdagno 5
Birmingham 4
Bratislava 4
Buffalo 4
Carpi 4
Falls Church 4
Hamburg 4
Hong Kong 4
Kuala Lumpur 4
Luni 4
Mountain View 4
Pune 4
Senago 4
Sesto Fiorentino 4
Shenyang 4
Tianjin 4
Ahmedabad 3
Totale 2.969
Salva come PNG Salva come JPEG
Nome #
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 243
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 239
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 223
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 165
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 153
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 149
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 117
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 111
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 109
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 106
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 105
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 101
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 100
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 98
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 95
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 91
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 87
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 86
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 85
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 81
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 77
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 76
Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin 74
4-Hydroxy-1H-1,2,3-Triazol-5-yl moiety as bioisoster of carboxylic group. Synthesis and pharmacological ionotropic glutamate receptors characterization of Glu analogues 71
Synthesis and Structural Characterization of Regio Substituted 4-Hydroxy-1H-1,2,3-triazols as Possible Tool in Bioisosteric Applications 71
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 71
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 70
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 70
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 69
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 68
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 66
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy 65
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 64
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 59
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 58
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 57
Design and synthesis of a library of pyrazolo[1,5-a]pyridine fluorophores for developing new fluorescent probes 57
Use of the 4-hydroxy-triazole moiety as a bioisosteric tool in the development of selective ligands for subtypes AMPA receptor 51
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 48
The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses [Calistri A.*, Luganini A.*, co-first author] 48
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 46
Dihydroorotate dehydrogenase inhibitors in anti-infective drug research 46
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 46
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 45
Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems 44
Hydroxypyrazolol[1,5-a]pyridine as a fluorescent carboxylic acid isostere: development of new fluorescent 4-PHP analogues 43
Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with hydroxypyrazole core: new scaffolds against malaria disease 43
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 43
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 43
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 42
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 41
Hydroxylated heterocycles as a bioisosteric tool to Modulate the carboxylic function into design potent human Dihydroorotate Dehydrogenase inhibitors 41
Synthesis, physiochemical proprieties and application of hydroxyazole systems as carboxylic acid isoster 40
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 40
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 39
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 38
Antileishmanial activity of some 4-phenyl-3-amino-1H-pyrazols designed as CRK3 kinase inhibitors 37
Develop of new fluorescent probe to target hDHODH enzyme 35
Hydroxyazoles as acid isosteres and their drug design applications—Part 1: Monocyclic systems 35
A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats 35
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 35
New human dihydroorotate dehydrogenase inhibitors able to restore myeloid differentiation in AML 32
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 32
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 29
Toward a Bioisosteric Alkahest: Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 29
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 28
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 27
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER 27
Synthesis of [18F] Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 26
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 25
Improving the fluorescent profile of pyrazolo [1,5-a]pyridine fluorophores for developing new fluorescent probes 24
Use of the 4-Hydroxytriazole Moiety as a Bioisosteric Tool in the Development of Ionotropic Glutamate Receptor Ligands 20
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 16
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 16
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 14
The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis 13
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 12
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 11
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role. 11
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 10
NEW AKR1C3 INHIBITORS WITH BENZOISOXAZOLE CORE: DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY TO TARGET PROSTATE CANCER 9
Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication 8
Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study 6
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 6
Turning the light on with pyrazolo[1,5-A]pyridine: exploring it’s fluorescent properties for the design of new fluorosteric compounds 4
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer 4
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies 4
Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor 4
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role 4
Totale 5.142
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.484
article - articoli 0
book - libri 0
conference - conferenze 11.607
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.091
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201980 0 0 0 0 0 0 0 0 0 0 40 40
2019/2020520 39 24 10 41 22 64 102 31 36 61 58 32
2020/2021505 55 55 34 30 40 15 32 16 69 48 39 72
2021/2022892 41 17 56 62 35 41 39 38 20 116 261 166
2022/20231.675 160 195 65 155 134 401 126 103 136 50 87 63
2023/2024827 113 114 67 65 60 99 161 37 13 96 2 0
Totale 5.142